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INTRODUCTION 
 Sleep can be conceptualized as a motivated behaviour, something the 
organism “needs” to do in order to survive and for which there is a pressure to 
perform.1  
 Sleep is a process the brain requires for proper functioning.2  Humans spend 
about a third of their lives in sleep. Sleep is a state of inactivity accompanied by 
loss of awareness and a markedly reduced responsiveness to environmental 
stimuli.3 
 Sleep disorders are frequent in the general population. Up to 30% of adults 
complain of insomnia.4 Primary sleep disorders include dyssomnias and 
parasomnias. Dyssomnias can be characterized by disturbance in amount, quality, 
or timing of sleep. Parasomnias are characterized by abnormal behaviours or 
physiological events associated with sleep.2  There are number of interesting and 
common irregularities of sleep, some of which approach serious extremes.  
Inadequate sleep leads to daytime tiredness, lack of energy, irritability, poor 
concentration, anticipatory anxiety and psychiatric problems like anxiety & 
depression. The psychologic and physiologic benefits of sleep are of paramount 
importance and it is increasingly recognized that disruption of sleep increases the 
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risks for a number of medical diseases including stroke, hypertension and coronary 
disease.5 
 The neurotransmitters and neuromodulators that may regulate sleep-wake 
cycle are serotonin, norepinephrine, acetylcholine, dopamine, γ aminobutyric acid 
(GABA), adenosine, interleukins, prostaglandins and certain endogenous sleep 
factors like peptides and uridine.2 
Anxiety is a feeling of apprehension, uncertainty or tension stemming from 
the anticipation of an imagined or unreal threat. Approximately 4-6% of population 
suffers from anxiety. It is so severe that it disrupts routine life functions. Hence 
anxiolytic drugs are extensively prescribed. 6 
Any person facing a challenging or threatening task for which he may feel 
unprepared, experiences some degree of nervousness and anxiety. Anxiety is then 
not abnormal, and the alertness and attentiveness that accompany it may actually 
improve performance up to a point, after which increasing anxiety causes a rapid 
decline in performance.5 Indeed it is a universal human emotion, closely allied with 
appropriate fear and presumably serving psychobiologically adaptive purposes. 
Anxiety is a cardinal symptom of many psychiatric disorders. Anxiety is an 
inevitable component of many medical and surgical conditions. Sometimes no 
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treatable primary illness is found.7   
 The disability and health costs caused by anxiety are high and comparable 
with those of other common medical conditions such as diabetes, arthritis or 
hypertension.3 
Anxiety states & sleep disorders are common problems and hence sedative 
hypnotics & anxiolytics are among the most widely prescribed drugs today. 
 A broad range of pharmacologic agents are available to treat anxiety and  
sleep disorders namely Benzodiazepines, Tricyclic antidepressants, Monoamino 
oxidase inhibitors, Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and 
Noradrenaline Reuptake Inhibitors (SNRIs), Antiadrenergic agents, Antipsychotic 
drugs, Hydroxyzines and Buspirone. 
 Benzodiazepines are the most commonly prescribed agents. They are 
primarily introduced for their sedative, hypnotic and anxiolytic effects. They are 
also preferred for preanaesthetic medication.8  They can produce anaesthesia 
similar to barbiturate but not used in general anaesthesia because of prolonged 
amnesia and sedation. Nowadays it is also indicated for other diseases like panic 
disorders, phobia, epilepsy, bipolar disorders and muscle spasms. Their drawbacks 
include excessive sedation, cognitive & psychomotor impairment, paradoxical 
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effects, tolerance and dependence.9 
 Hence there is always a search for drugs with lesser side effects. 
 ‘Clonidine’, an α2 agonist known for its antihypertensive effect also 
possesses sedative, hypnotic, anxiolytic, analgesic and anti-inflammatory 
properties. Clonidine is also useful in selected patients receiving anaesthesia 
because it increases hemodynamic stability and decreases the anaesthetic 
requirement.7 
 Hence the present study is undertaken to find out the sedative, hypnotic and 
anxiolytic effects of clonidine in comparison with the standard drug diazepam in 
mice. 
 
 
 
 
 
 
  
 
 
 
AIM 
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AIM 
 
 The aim of present study is to evaluate the sedative, hypnotic and anxiolytic 
effects of clonidine in comparison with diazepam in mice.    
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 Sleep, an elemental phenomenon of life and an indispensable phase of 
human existence represents one of the basic 24-hr (circadian) rhythms traceable 
through all mammalian, avian, and reptilian species.  
 The neural control of circadian rhythms is thought to reside in the anterior 
region of the hypothalamus, more specifically in the suprachiasmatic nuclei. 
Lesions in these nuclei result in disorganization of the sleep-wake cycles as well as 
of the rest-activity, temperature and feeding rhythms.5 
Essential relationships between a troubled mind and disturbances in sleep 
have been recognized since antiquity.1 Sleep disturbances are particularly pertinent 
to psychiatrists and other mental health professionals because these complaints are 
frequently associated with depression, anxiety, substance abuse, obsessive-
compulsive disorders, psychosis, acute & chronic stress, and many other disorders. 
The neuroscience of sleep regulation, in addition is important to understand the 
pathophysiology of psychiatric disorders and the mechanism of action of 
psychoactive drugs. 
 Many sleep disorders are life threatening either directly (e.g. fatal familial 
insomnia and obstructive sleep apnea) or indirectly as result of sleep related 
accidents. 
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  The 24 hour sleep-wake rhythm is driven by the suprachiasmatic 
nuclei synchronized to the environmental light-dark cycle by Zeitgebers. A number 
of sleep disorders specifically involve disturbances of the circadian sleep-wake 
system (jetlag, shift work schedules). The flexibility of the circadian system 
diminishes with age, so the elderly suffer more from jetlag and shift work 
schedules. 
 The frequency and severity of insomnia increase with age in both sexes. 
Total sleep time decreases from an average of 8 hours daily in young adulthood to 
about 6 hrs daily at the age of 90. This is accompanied by more nocturnal 
arousals.5 
Classification of primary sleep disorders in DSM IV 4 
Dyssomnias 
 Primary insomnia 
 Primary hypersomnia 
 Narcolepsy 
 Breathing related sleep disorder 
 Circadian rhythm sleep disorder 
 Dyssomnia not otherwise specified 
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Parasomnias 
 Nightmare disorder (dream anxiety disorder) 
 Sleep terror disorder 
 Sleep-walking disorder 
 Parasomnia not otherwise specified 
Sleep disorder related to another mental disorder 
 Insomnia 
 Hypersomnia 
Other sleep disorders 
 Secondary sleep disorder due to a general medical condition 
 Substance-induced sleep disorder 
Primary insomnia 
 Primary insomnia is diagnosed only after a patient complains of 
sleeplessness or poor quality of sleep for one month or more. The insomnia, or 
consequent sleepiness must produce significant distress or impair activities of daily 
life.2 
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 Insomnia in clinical practice is usually secondary to other disorders, notably 
painful physical conditions, depressive disorders and anxiety disorders, and is 
often clinically overlooked. 
 In about 15% of cases of insomnia, no cause can be found (Primary 
insomnia).   
Primary hypersomnia 
 Patients complain that they are unable to wake completely until several 
hours after getting up. During this time they feel confused and possibly disoriented 
(‘Sleep drunkenness’).4 
Narcolepsy 
 Narcolepsy is a syndrome of unknown origin characterized by irresistible 
urges to sleep. These sleep attacks typically occur two to six times a day and last 
for 10-20 minutes. They may occur at inappropriate times (e.g.) while eating, 
talking, or driving. Symptoms typically appear in the second decade of life. It is 
usually associated with one or more of the following symptoms: Cataplexy (brief 
episodes of sudden bilateral loss of muscle tone in association with intense 
emotion), sleep paralysis (inability to move or speak when awaking from sleep) 
and hypnagogic hallucinations (frightening hallucinations experienced during sleep 
onset or waking).10 
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Breathing related sleep disorders 
 This syndrome consists of daytime drowsiness together with periodic 
respiration and excessive snoring at night. It is usually associated with upper 
airway obstruction and typically occurs in middle aged overweight patients. 
Circadian rhythm sleep disorder 
(Sleep-wake schedule disorders)  
 Shift work type and jetlag are familiar forms of circadian rhythm sleep 
disorder.4 
Parasomnias  
 Parasomnias can simply be defined as intermittent undesirable events arising 
from sleep that are not epileptic in nature. The spectrum ranges from visual 
imagery at sleep onset to complex motor behaviours, occasionally with violent 
components.11 
 A nightmare is an awakening from REM sleep to full consciousness with 
detailed dream recall. Peak frequency occurs around the ages of five or six years. 
Night terrors are less common and, begin and end in childhood. There is no dream 
recall. 
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Sleep walking is an automatism occurring during deep non-REM sleep, 
usually in the early part of the night.  It is most common between the ages of 5 and 
12 years.4 
Insomnia related to another mental disorder 
 Approximately 80% of patients with psychiatric disorders describe sleep 
complaints. Sleep disturbances are common in patients suffering from depression, 
alcoholism, mania, anxiety disorders and schizophrenia. 
Neurogenic sleep disorders 
 Sleep disruption can occur in dementia, epilepsy, Parkinson’s disease, 
Huntington’s chorea, Tourette syndrome, headache syndromes (migraine or cluster 
headache). 
Insomnia due to other medical disorders 
 Sleep may be impaired due to chronic pain from rheumatologic disorders, 
pulmonary diseases (asthma, COPD), cardiac ischemia, hyperthyroidism, chronic 
renal failure, and liver failure.12 
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Medication, drug or alcohol – dependent insomnia 
Alcohol, anxiolytics, opioids and sedative hypnotics promote sleep by 
sedation. But the sleep is of poorer quality though of greater quantity. Psycho 
stimulants like cocaine, amphetamine, caffeine-containing beverages, 
sympathomimetics, theophylline and antidepressants cause CNS arousal and 
produce insomnia. 
Pathophysiology of sleep disorders: 13 
 The physiological mechanisms regulating the sleep-wake rhythm are not 
completely known. There is evidence that histaminergic, cholinergic, 
glutamatergic, and adrenergic neurons are more active during waking than during 
the NREM sleep stage. Through the ascending thalamopetal projections, these 
neurons excite thalamocortical pathways and inhibit GABA-ergic neurons. During 
sleep, input from the brainstem decreases, giving rise to diminished 
thalamocortical activity and disinhibition of the GABA neurons. The shift in 
balance between excitatory and inhibitory neuron groups underlies a circadian 
change in sleep propensity, causing it to remain low in the morning, to increase 
towards early afternoon (midday siesta), then to decline again, and finally to reach 
its peak before midnight. 
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 As the margin between excitatory and inhibitory activity decreases with age, 
there is an increasing tendency towards shortened daytime sleep periods and more 
frequent interruption of nocturnal sleep. Imbalance between the excitatory and 
inhibitory neurotransmission with more shift towards excitatory system underlies 
many of the sleeping disorders.  
Anxiety disorders 
 Anxiety disorders are the most common psychiatric disorders in the world 
among both children and adults. Much of the emotional and economic burden 
caused by these disorders could be alleviated by improving the diagnosis and 
treatment.14  In most cases, women are more likely to have anxiety disorders than 
men, a phenomenon that still begs for adequate explanation. Of particular interest 
in the finding that social phobia is more common in women than men. 
 Beard in 1869 introduced the term neurasthenia, when lesser degrees of 
anxiety were grouped with minor depressive disorders. The first step in identifying 
anxiety disorder was taken by Westphal in 1871 who described the syndrome of 
agoraphobia. At that time it appeared that the word ‘anxiety’ was derived from 
mistranslation of Freud’s word for fear (angst). In 1895, Freud separated anxiety 
disorders from neurasthenia and suggested the name anxiety neurosis.9 
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 Everyone experiences anxiety. It is characterized most commonly as a 
diffuse, unpleasant, vague sense of apprehension often accompanied by autonomic 
symptoms such as headache, perspiration, palpitations, tightness in the chest, mild 
stomach discomfort and restlessness, indicated by an inability to sit or stand still 
for long.15 
Trait anxiety refers to a lifelong pattern of anxiety as a feature of 
temperament and state anxiety refers to episodes of anxiety that are tightly bound 
to specific situations and that do not persist after the provoking situation has 
abated. Free floating anxiety is characterized by a persistently anxious mood in 
which the cause is unknown. But situational anxiety occurs only in relation to 
specific occasions or external stimuli. 
Recent studies also suggest that chronic anxiety disorder may increase the 
rate of cardiovascular-related mortality. Another fascinating aspect of anxiety 
disorders is the exquisite interplay of genetic and experiential factors. 
  While there is little doubt that abnormal genes predispose to 
pathological anxiety states, evidence clearly indicates that traumatic life events and 
stress are also etiologically important. Genetic susceptibility to an anxiety disorder 
becomes an actual anxiety disorder when some set of environment influences 
15 
 
causes anxiety proneness genes to become active.  Medical illness, drugs, toxins 
and substance abuse also play a role in the etiology of anxiety disorder.2 
It is important to distinguish among the various anxiety disorders and 
identify possible comorbidities because of difference in treatments, complications 
and prognosis. 
Classification of Anxiety disorders 9 
According to DSM IV, anxiety disorders are classified as follows: 
1. Panic disorder without agoraphobia 
2. Panic disorder with agoraphobia 
3. Agoraphobia without history of panic disorder 
4. Specific phobia 
5. Social phobia 
6. Obsessive compulsive disorder 
7. Post traumatic stress disorder 
8. Acute stress disorder 
9. Generalized anxiety disorder 
10. Anxiety disorder due to a general medical condition 
11. Substance induced anxiety disorder 
12. Anxiety disorder not otherwise specified 
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Panic disorder 
  Panic disorder, the most commonly encountered anxiety disorder in 
medical settings, is also the most disabling, with financial, social, and occupational 
impairment.16  The main feature of panic disorder is recurrent, unexpected panic 
attacks accompanied by characteristic physical symptoms such as pounding of 
heart, sweating, hot flushes or chills, trembling/shaking, breathing difficulties, 
chest pain, nausea, diarrhoea. 
 Usually the attack lasts no more than 20 – 30 minutes, reaches peak within 
10 minutes. 
 Secondary to panic attacks, many patients develop agoraphobia which is 
anxiety about being in places or situations in which escape might be difficult.17 
Generalized anxiety disorder 
 According to DSM-IV, generalized anxiety disorder is characterized by 
excessive and uncontrollable anxiety or worry persisting for at least six months, 
combined with three of six additional symptoms (“restlessness or feeling keyed up 
or on edge,” “being easily fatigued,” “difficulty concentrating or mind going 
blank,” “irritability,” “muscle tension,” and “sleep disturbance”). Recent 
epidemiological studies indicate that generalized anxiety disorder is one of the 
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most common anxiety disorders; despite such prevalence, a paucity of research on 
its neurobiology exists. 
Social phobia 
 According to DSM-IV social phobia is characterized by fear of social or 
performance situations involving exposure “to unfamiliar people or possible 
scrutiny by others” combined with fear of acting in a way that “will be humiliating 
or embarrassing”. The exposure also almost invariably provokes an anxiety 
reaction, similar to a situationally bound or predisposed panic attack. The 
situations are avoided or else are endured with intense anxiety or distress. 
 
Specific phobia 
 According to DSM – IV, specific phobia is characterized by a “marked and 
persistent fear that is excessive or unreasonable” brought on “by the presence or 
anticipation of a specific object or situation (e.g., flying, heights, animals, 
receiving an injection, seeing blood)”. The response may take the form of a 
situationally bound or predisposed panic attack, and the phobia causes marked 
distress. A prominent vasovagal response was observed in a subgroup of patients. 
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Post traumatic stress disorder 
 DSM-IV defines posttraumatic stress disorder (PTSD) as a disorder in which 
a person has been exposed to a traumatic event or events that included “actual or 
threatened death or serious injury, or threat to the physical integrity of self or 
others.” and “the person’s response involved intense fear, helplessness or horror.” 
Symptoms of increased arousal are also present and can include sleep disturbance, 
irritability, poor concentration, and exaggerated startle reflex.  
Obsessive compulsive disorder 
 According to DSM-IV, obsessive-compulsive disorder (OCD) is 
characterized by repetitive thoughts, impulses, or images that are intrusive and 
inappropriate and cause anxiety or distress, or repetitive behaviours that the person 
feels driven to perform in response to an obsession or rigid rules that must be 
applied. These persons also recognize that the obsessions are a product of their 
own mind. The obsessions or compulsions are time consuming or interfere with 
role functioning. 
 OCD is unique among the anxiety disorders by appearing to be much more 
dominated by cognitive and related complex behavioural symptomatology, with 
autonomic dysregulation playing little role. 
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Acute stress disorder 
 Acute stress disorder is anxiety in response to a recent extreme stress. 
Although in some respects it is normal and understandable reaction to an event, the 
problems associated with it are not only the severe distress the anxiety causes but 
also the risk that it may evolve into a more persistent state.3 
Anxiety disorders due to general medical condition 
 Anxiety symptoms are an inherent part of the initial clinical presentation of 
several diseases, thus complicating the distinction between anxiety disorders and 
medical disorders. They usually will subside as the medical situation stabilises. 
Causes of anxiety disorder secondary to a general disorder 17 
Angina, Arrhythmias, Myocardial infarction 
Cushing’s disease 
Hyperparathyroidism 
Hyperthyroidism 
Dementia 
Migraine 
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Parkinson’s disease 
Neoplasm 
Asthma 
Chronic obstructive pulmonary disease 
Anemia 
Systemic lupus erythematosus  
Drug induced anxiety 
 CNS stimulants can cause anxiety in a dose dependent manner.   
Pathophysiology of Anxiety disorder 9  
 Several preclinical evidences now indicate that the amygdala plays a crucial 
role in the development of stress response, fear and anxiety. 
 The central nucleus of amygdala has direct projections to a variety of 
anatomical areas that might mediate many of the symptoms of fear and anxiety. 
 At least three neurotransmitter systems appear to modulate the symptoms of 
many anxiety disorders. These are the norepinephrine, serotonin, and GABAergic 
systems. 
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Norepinephrine 
 Anxiety disorder patients have poorly regulated noradrenergic system that 
has occasional bursts of locus ceruleus. Stimulation of local ceruleus produces a 
fear response in animals and ablation of that area inhibits the ability of the animals 
to form a fear response. 
 Human studies have found that, in patients with panic disorder, α-adrenergic 
agonists (e.g. isoproterenol) and α2 adrenergic antagonists (e.g. yohimbine) can 
produce frequent and severe panic attacks. Conversely clonidine, an adrenergic 
agonist reduces anxiety symptoms in some experimental and therapeutic situations. 
Serotonin 
 Observations regarding the role of serotonin are contradictory. On the one 
hand, clomipramine (serotonergic antidepressant) and buspirone (5HT1A receptor 
agonist), are beneficial in the treatment of anxiety disorders. On the other hand 
serotonergic hallucinogens (e.g. Lysergic acid diethylamide or LSD), and 
fenfluramine (which causes release of serotonin) are associated with development 
of both acute and chronic anxiety disorders. 
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GABA 
 There is inconclusive evidence regarding the role of GABA in anxiety 
disorders. The effectiveness of benzodiazepines, which enhance activity of GABA 
at the GABAA receptor in the treatment of some anxiety disorders and occurrence 
of panic attacks in panic disorder patients by flumazenil (a benzodiazepine 
antagonist) are suggestive of the role of GABA in the genesis of anxiety disorder. 
 Studies of patients with post traumatic stress disorder have revealed a down 
regulated hypothalamic-pituitary-adrenal axis with reduced secretion of cortisol, 
presumably as a result of chronically increased production of corticotropin 
releasing factor. 
 One model relevant to anxiety and panic puts forth that the serotonin 
pathway is originating in the dorsal raphe nucleus. This pathway involves post 
synaptic serotonin 5HT2A/2C and 5HT3 receptor activation. Such a pathway is 
relevant to generalized anxiety disorder. A separate pathway originating in dorsal 
raphe nucleus involves innervation of the periventricular and periaqueductal gray 
region. This pathway is relevant to panic attacks mediated by 5HT2A/2C and 5HT1A 
postsynaptic receptors. In chronic stress activation of 5HT1A receptor promotes 
resistance to such stress by disconnecting the aversive events from processes 
underlying appetitive and social behaviours. 
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 The locus ceruleus noradrenergic and dopaminergic systems are believed to 
increase autonomic arousal and vigilance in response to threat. Overstimulation of 
such adaptive mechanisms by repeated or chronic stressors as well as deficits in 
function of components of these systems could theoretically lead to pathological 
responses observed in anxiety disorders. 
Pharmacotherapy of sleep disorders and anxiety disorders 
 The primary use of drugs, classified as sedative, hypnotic and anxiolytic is 
to produce calmness and sleep. A sedative drug reduces daytime activity and calms 
the recipient; an anxiolytic drug reduces pathological anxiety; and a hypnotic drug 
produces drowsiness and facilitates the onset and maintenance of sleep. In addition 
to inducing sleep and reducing pathological anxiety, the various sedative and 
hypnotics are used as antiepileptic agents, muscle relaxants, antipanic agents, in 
the treatment of alcohol withdrawal states and as anaesthetic agents. 
History of Sedative and Hypnotic drugs 7 
 The first agent used as sedative and hypnotic was bromide (1853). Other 
sedative hypnotic drugs used before 1900 were chloral hydrates, paraldehyde, 
urethane and sulfonal. Barbital was introduced in 1903 and phenobarbital in 1912. 
Barbiturates were most commonly used sedative-hypnotics till 1961 when 
24 
 
chlordiazepoxide was introduced. Since then many benzodiazepines were 
synthesized and marketed.                                                                                                                                                              
   Most of the benzodiazepines that have reached the market place were 
selected for high anxiolytic potency in relation to their depression of CNS function. 
However all benzodiazepines possess sedative, hypnotic properties to varying 
degrees. These properties are exploited extensively clinically, especially to 
facilitate sleep. 
Classification of Anxiolytic and Hypnotic drugs 18 
(i)  Benzodiazepines: 
Hypnotics    Anxiolytics    Anticonvulsants 
Diazepam     Chlordiazepoxide   Diazepam 
Nitrazepam    Diazepam        Clonazepam 
Lorazepam      Alprazolam    Clobazam 
Temazepam       Oxazepam      
Triazolam    Lorazepam 
Midazolam    Flurazepam 
Flurazepam   
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(ii) Non benzodiazepine Hypnotics: 
Zopiclone, Zolpidem, Zaleplon 
(iii) Atypical Anxiolytics: 
Buspirone, Ipsapirone, Gepirone 
(iv) Beta adrenoceptor antagonist: Propranolol 
(v) Barbiturates: 
Long acting  Short acting  Ultra short acting 
Phenobarbital  Pentobarbital  Thiopental 
Mephobarbital  Secobarbital   Methohexital 
    Amobarbital 
(vi) Miscellaneous group: 
Melatonin, Triclophos, Hydroxyzine, Promethazine 
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Management of insomnia 
 Management of insomnia includes pharmacological and non-
pharmacological treatment.19  The side effects of hypnotic medications must be 
weighed against the sequelae of chronic insomnia which includes a fourfold 
increase in serious accidents. 
Categories of insomnia 7   
 National Institute of Mental Health Consensus Development Conference 
(1984) divided insomnia into 3 categories. 
1. Transient insomnia: 
 Transient insomnia lasts less than 3 days and usually is caused by a brief 
environmental or situational stressor. It may respond to sleep hygiene rules. If 
hypnotics are prescribed they should be used at the lowest dose and for only 2 to 3 
nights. 
2. Short term insomnia: 
 Lasts from 3 days to 3 weeks and usually is caused by a personal stressor 
such as illness, grief or job problems. Sleep hygiene education is the first step. 
Hypnotics may be used adjunctively for 7 to 10 nights. 
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3. Long term insomnia: 
 Long term insomnia is insomnia that has lasted for more than 3 weeks. No 
specific stressor may be identified. A more complete medical examination is 
necessary. Insomnia caused by major psychiatric illness often responds to specific 
pharmacological treatment for that illness. 
 Adequate control of anxiety in patients with anxiety disorders often 
produces adequate resolution of the accompanying insomnia. 
 The profound insomnia of patients with acute psychosis owing to 
schizophrenia or trauma usually responds to dopamine receptor antagonists. 
Non pharmacological treatments for insomnia 2      
        Sleep hygiene refers to basic rules designed to provide circumstances and 
conditions conducive to sleep. They include the following list of things: 
Universal sleep hygiene: 
 This includes maintaining a regular sleep-wake schedule, daily exercise, 
insulating the bedroom against excessive noise, light, cold and heat; eating a light 
snack before retiring if hungry and setting time aside to relax before getting into 
bed. 
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Stimulus control therapy: 
 The first rule is to go to bed only when sleepy. Second, use bed only for 
sleeping. Rule three instructs the patient not to lie in bed and become frustrated if 
unable to sleep. Go to another room and do something nonarousing until sleepiness 
returns. 
 Rule four is to awaken at the same time every morning, regardless of 
bedtime. The final rule is to totally avoid napping. 
Sleep restriction therapy: 
 Restricting time in bed can help consolidate sleep for patients who find 
themselves lying awake in bed unable to sleep. 
Relaxation therapy: 
 Self-hypnosis, progressive relaxation and deep breathing exercise are all 
effective if they produce relaxation. 
Pharmacological Treatment of insomnia 
Commonly used compounds are benzodiazepines and nonbenzodiazepines. 
Selecting an appropriate drug depends on the duration of action.19   
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Benzodiazepines 
 Benzodiazepines are the most frequently prescribed drugs for treating 
insomnia and are Food and Drug Administration (FDA) labeled for the treatment 
of insomnia. All benzodiazepine receptor agonists are effective as sedative 
hypnotics. Benzodiazepines relieve insomnia by reducing sleep latency and 
increasing total sleep time. They increase stage 2 sleep while decreasing REM, 
stage 3 and stage 4 sleep.17   
Mechanism of action 
 Specific cellular membrane binding sites were determined by Young in 
1981. These sites are confined to the CNS and are predominately localized in 
neuronal surface membranes. The distribution within the CNS is extensive, with 
concentrations in every brain region. The action of benzodiazepines is mediated 
through a facilitation of the GABAergic transmission at specific receptor sites.20 
 Benzodiazepines bind to the GABAA receptor at the 1, 2, 3, 5 subunits. 
Benzodiazepines with high affinity at 1 subunit is associated with sedation, 
hypnosis and anticonvulsant activity and those with affinity for 2 subunits 
mediate anxiolytic and muscle relaxant actions.21 
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 When benzodiazepines bind to the GABAA receptor, it opens the chloride 
ion channels. A widening of the channels, with an increase in ion conductance, 
occurs to alter the membrane potential and to prevent an action potential. 
Benzodiazepines act by increasing the frequency of openings of the GABA-
modulated chloride channels.20  
Pharmacokinetics 
   Benzodiazepines are effective orally. There are marked pharmacokinetic 
differences among benzodiazepines because they differ in lipid soluability by more 
than 50 fold. Absorption from intramuscular sites is irregular except for lorazepam. 
Benzodiazepines are metabolized by liver and excreted as glucuronide conjugates 
in urine. Many of them are converted to active metabolites such as N-
desmethyldiazepam, which has a half-life of about 60 hours, and which accounts 
for the tendency of many benzodiazepines to produce cumulative effects and long 
hangovers when they are given repeatedly.22 
  In psychiatric disorders, the benzodiazepines are usually given orally; in 
controlled medical environments (e.g. ICU), where the rapid onset of respiratory 
depression can be assessed, they are often given intravenously. 
 
31 
 
 The longer acting benzodiazepines are used for the treatment of alcohol 
withdrawal and anxiety symptoms; the intermediate drugs are useful as sedatives 
for insomnia (e.g., lorazepam), while short acting agents (e.g., midazolam) are 
used for medical procedures such as endoscopy.23     
Side effects 
 Side effects are dose dependant and vary according to the pharmacokinetics 
of the individual benzodiazepine. High doses of benzodiazepines with long or 
intermediate elimination half-lives have a greater potential for producing day time 
sedation and performance impairment. They cause excessive drowsiness, 
psychomotor in-coordination and cognitive deficits. Tolerance to hypnotic effect 
may develop with time. Rapidly eliminated benzodiazepines have less potential for 
daytime sedation.17 
Drug interactions 23 
Antacids - Decreased absorption of benzodiazepines 
Cimetidine - Increased half-life of diazepam and triazolam 
Contraceptives – Increased levels of diazepam and triazolam 
Disulfiram  - Increased duration of action of benzodiazepines 
Rifampin - Decreased plasma diazepam  
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Non-Benzodiazepine GABAA Agonists 
 Zolpidem, zaleplon and eszopiclone are non benzodiazepine hypnotics that 
selectively bind to GABAA receptors and effectively induce sleepiness. 
Zolpidem: 
 It is an imidazopyridine, comparable in efficacy to benzodiazepine hypnosis 
and is effective for reducing sleep latency, nocturnal awakenings and increasing 
total sleep time. It does not appear to have significant effects on next day 
psychomotor performance. Recommended daily dose is 10mg and can be increased 
to 20mg per night. It should be taken on an empty stomach and treatment optimally 
should not exceed four weeks to minimize tolerance and dependence. 
Zaleplon: 
Zaleplon is a pyrazolopyrimidine. It has a rapid onset of action, and a half 
life of one hour. It is effective for decreasing the time of sleep onset, but not for 
reducing night time awakening or for increasing total sleep time. Because of its 
short half life zaleplon has no effect on next day performance.17 
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Eszopiclone:       
 Eszopiclone is an oral nonbenzodiazepine hypnotic utilizing BZ1 receptor 
similar to zolpidem and zaleplon and used for treating insomnia. It is rapidly 
absorbed and mainly excreted in urine. It is effective for up to 6 months compared 
to a placebo.24     
Antihistamines:  
 Antihistamines are included in many over the counter sleep agents. They are 
effective in the treatment of mild insomnia and are generally safe. 
Diphenhydramine and doxylamine are more sedating. They have the disadvantage 
of anticholinergic side effects. 
Antidepressants: 
 They are alternatives for patients with non-restorative sleep who should not 
receive benzodiazepines, especially those who have depression, pain or a risk of 
substance abuse. 
 Sedating antidepressants such as amitriptyline and nortriptyline are effective 
for inducing sleep continuity. 
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 Trazodone is popular for the treatment of insomnia in patients prone to 
substance abuse, as dependence is not a problem. It is used in patients with 
Selective Serotonin Reuptake Inhibitor (SSRI) and bupropion induced insomnia. 
Caution should be exercised to avoid serotonin syndrome when used in these 
combinations.17 
Melatonin: 
 Melatonin is a hormone produced in the pineal gland from the amino acid 
tryptophan. The secretion of melatonin follows a diurnal rhythm. It acts as a 
chronobiotic which therapeutically adjusts the timing of circadian rhythm. It is 
primarily used to alleviate symptoms of jetlag and other disorders resulting from 
delay of sleep in the dose of 3 mg two hours before bedtime.18 
Ramelteon: 
Ramelteon is a melatonin receptor agonist that has recently been approved 
for the treatment of sleep onset insomnia.17 It is a novel hypnotic drug. It is 
selective for the MT1 and MT2 melatonin receptors. Ramelteon reduces the 
latency of persistent sleep with no effects on sleep architecture and no rebound 
insomnia. Ramelteon is not a controlled substance and can be a viable option for 
patients with a history of substance abuse.25 
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Valerian: 
 Valerian is an herbal sleep remedy. The mechanism of action may involve 
increasing concentrations of  aminobutyric acid [GABA].17   
History of Anxiolytic drugs 26 
Modern medical anxiolysis began with the introduction of paraldehyde and 
bromides around the turn of the century, followed by the first medical use of 
barbiturates in 1903. 
  The development of non-barbiturate, non-benzodiazepine hypnotic 
drugs in the 1930s did not address any of the deficiencies of barbiturates and 
proved more problematic in many cases. Meprobamate, and tybamate possess very 
low therapeutic index, methaqualone is highly addicting and fatal in over dose, 
glutethimide overdose can result in convulsions and coma.  
  The synthesis in 1957 of the first benzodiazepine,  chlordiazepoxide, 
heralded a new era of safe and effective medical management of anxiety. Because 
of their safety, efficacy and high therapeutic index, benzodiazepines have for the 
most part replaced barbiturates and the non barbiturate, non benzodiazepine type 
drugs. 
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 The demonstration in the early 1960s that imipramine controls panic attacks 
was the first evidence that antidepressant drugs may alleviate anxiety and that this 
effect may be independent of their antidepressant property. Parallel to the work 
with imipramine in the United States, British investigators found that another class 
of antidepressants, monoamine oxidase inhibitors (MAOIs) specifically benefit 
hysterical patients with phobic symptoms. Since these patients show many features 
of panic disorder and agoraphobia, tricyclic and tetracyclic drugs and MAOIs 
quickly became the first line treatment choice in panic disorder. 
 Of the many subsequently introduced antidepressants with anxiolytic 
properties, fluoxetine was the next milestone in the pharmacology of anxiety. The 
efficacy of serotonergic drugs in the treatment of panic disorder and obsessive-
compulsive disorder significantly advanced the treatment of these anxiety disorders 
and gave rise to new theories implicating the serotonergic system in the 
neurobiology of anxiety. 
 In addition to benzodiazepines and several classes of antidepressants 
currently available anxiolytic agents include β-adrenergic receptor antagonists and 
the azapyrone buspirone. New drug development targets include partial 
benzodiazepine agonists and reverse benzodiazepine antagonists, neurosteroids, 
neuropeptide agonists and antagonists such as cholecystokinin B antagonists, 
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corticotrophin-releasing factor antagonists, neuropeptide Y agonists and 
serotonergic agents acting on specific serotonin receptor subtypes agonists, 5-HT1A 
agonists and 5-HT2 and 5-HT3 antagonists. The accelerated drug development 
process promises highly effective anxiolytic agents with minimal adverse effects in 
the near future. 
 
Treatment of anxiety disorders 
 Nonpharmacological treatment: 
 Nonpharmacological methods for the treatment of generalized anxiety 
include behavioural and cognitive psychotherapy, meditation techniques and 
biofeedback.27  Psychotherapeutic interventions are often considered the first line 
intervention in anxiety disorders, particularly for patients with mild symptoms and 
for children. Cognitive behaviour therapy (CBT) is a specific type of 
psychotherapy and has the best evidence-based research supporting its use in 
anxiety disorders.14  Cognitive behaviour therapy (CBT) is the treatment of choice 
for panic disorder and general anxiety disorder.28  
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Pharmacological treatment: 
Benzodiazepines: 
 Benzodiazepines are the most important class of drugs used for treating both 
anxiety states and insomnia. Benzodiazepines achieve an anxiolytic effect by 
inhibiting synapses in the limbic system, a CNS region that controls emotional 
behaviour and is characterized by a high density of GABAA receptors. 
Benzodiazepines such as diazepam and alprazolam are used to mitigate chronic, 
severe anxiety, and the anxiety associated with some forms of depression and 
schizophrenia.29 
Buspirone:  
 These drugs act through non-GABAergic system and have low propensity to 
side effects compared to benzodiazepines. These drugs exert anxiolytic effects by 
acting as a partial agonist primarily at brain 5-HT1A receptors but also on brain 
dopamine D2 receptors. Hence by selective activation of inhibitory pre-synaptic 5-
HT1A receptor, they suppress 5-HT neurotransmission through neuronal system. 
 The antianxiety effect of buspirone appears after a week of administration of 
the drug; therefore, the drug is indicated in anxiety states and not in panic 
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disorders. As compared to diazepam, psychomotor impairment produced by 
buspirone is less. Buspirone is given orally in the dose of 5 – 15 mg, 2 -3 times a 
day. 
-adrenoceptor blockers: 
 Worrying situations and apprehensions associated with examinations, public 
address or job interviews are conducive to palpitation, tremors, gastrointestinal 
tract upset or even hypertension due to sympathetic overactivity. These symptoms 
in turn reinforce anxiety. Propranolol helps to suppress such performance anxiety 
through its beta blocking action.18 
Treatment of panic disorders 
 Panic attacks may be treated in several ways. A sublingual dose of 
lorazepam (0.5-2 mg) or alprazolam (0.5-1 mg) is effective for urgent treatment. 
For sustained treatment SSRIs are the initial drugs of choice. Sertraline starting at 
25 mg/day and increased after one week to 50 mg/day may be effective. High 
potency benzodiazepines may be used for symptomatic treatment as the 
antidepressant dose is titrated upward. Clonazepam (1-6 mg/day) orally and 
alprazolam (0.5-6 mg/day) orally are effective alternatives to antidepressants. Both 
drugs should be tapered to avoid withdrawal symptoms. Propranolol (40-160 
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mg/day orally) can mute the peripheral symptoms of anxiety without affecting 
motor and cognitive performance. Valproate has been found to be as effective as 
the antidepressants in panic disorder and is another useful alternative. 
Treatment of Phobic disorder 
 Global social phobias may be treated with SSRIs such as paroxetine, 
sertraline and fluvoxamine or monoamine oxidase (MAO) inhibitors in the same 
dosage as used for depression. 
 Gabapentin may be an alternative to antidepressants in the treatment of 
social phobia in a dosage of 300-3600 mg/day. 
 Specific phobia such as performance anxiety may respond to propranolol in 
the dose of 20-40 mg one hour prior to exposure.23 
Obsessive compulsive disorder (OCD) 
  Selective serotonin reuptake inhibitors are considered the first line 
agents in the treatment of obsessive compulsive disorder in children and adults as 
they are better tolerated. Among tricyclic antidepressants only clomipramine has 
specific antiobsessive effect, others are ineffective. Venlafaxine was shown to be 
equally effective as paroxetine. Clonazepam, a benzodiazepine that also affects 
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serotonergic neurotransmission, may be of some value in OCD, in treatment-
resistant cases. Few intractable cases of OCD may respond to electroconvulsive 
therapy (ECT).30 
Post-traumatic stress disorder (PTSD) 
 Psychotherapy should be initiated as soon as possible. Early treatment of 
anxious arousal with Beta-blockers (e.g. propranolol 80-160 mg orally daily) may 
lessen peripheral symptoms of anxiety (e.g. tremors, palpitations) and help prevent 
development of the disorder. 
 Antidepressant drugs, particularly selective serotonin reuptake inhibitors – in 
full dosage are helpful in ameliorating depression, and panic attacks in chronic 
PTSD. Sertraline and paroxetine are approved by the US Food and Drug 
administration (FDA) for this purpose. 
 The -blocking agent prazosin (2-10 mg orally at bed time) has been 
successfully used to decrease nightmares and improve quality of sleep in PTSD. 
Treatment of Generalized anxiety disorder 
 Benzodiazepines are the anxiolytics of choice in the acute management of 
generalized anxiety disorder. Antidepressants can be efficacious for the long term 
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management. In psychiatric disorders the benzodiazepines are usually given orally. 
The longer acting benzodiazepines are used for the treatment of alcohol withdrawal 
and anxiety symptoms. 
 Antidepressants are the first line medications for sustained treatment of 
generalized anxiety disorder, having the advantage of not causing serious 
physiologic dependency problems. Venlafaxine and duloxetine (serotonin and 
norepinephrine reuptake inhibitors) are FDA approved for generalized anxiety 
disorder. Buspirone is also effective in generalized anxiety disorder. 
 -blockers such as propranolol reduce the peripheral somatic symptoms. 
Phenobarbital, an anticonvulsant is a reasonably safe and inexpensive sedative.23  
 Several newer drugs are emerging as sedative, hypnotic, anxiolytics to 
overcome the adverse effects associated with the older drugs. Some drugs with 
anxiolytic effects exert their actions directly on adrenergic receptors. Although 
marketed for other purposes, -adrenergic antagonist – propranolol is in use for 
years in the management of several anxiety conditions. 
 Clonidine, an 2 agonist, originally introduced as an antihypertensive agent, 
widely used in several psychiatric disorders, is recently emerging as a sedative 
drug, and possess anxiolytic effects also.31 
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Clonidine – an overview 
 Clonidine is a presynaptic α2-adrenergic receptor agonist that is approved for 
use as an antihypertensive agent. Stimulation of α2-adrenergic receptors reduces the 
firing rate of noradrenergic neurons and reduces the plasma concentrations of 
norepinephrine. Because of widespread actions of the noradrenergic system, 
Clonidine has also been adopted for use as a psychopharmacological agent. It is 
also used as a pharmacological probe to assess central α2-receptor sensitivity in 
psychiatric disorders.  
Clonidine, an imidazoline derivative was synthesized in the early 1960s and 
found to produce vasoconstriction that was mediated by α receptors. The drug was 
initially developed as a topical nasal decongestant. During clinical testing, it was 
found to cause hypotension, sedation and bradycardia.32      Clonidine is a selective 
α2-adrenoceptor agonist with a α2: α1 ratio of 200:1. It is currently the only drug in 
this group available for use in anaesthetic practice.33  
Chemistry: 
 It is an imidazoline derivative and exists as a mesomeric compound. Its 
chemical name is 2-(2.6 - dichloroanilino) - 2 - imidazoline hydrochloride. 
Clonidine hydrochloride is an odourless, white crystalline powder soluble in water 
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and in dehydrated alcohol. Its molecular weight is 266.6. 34 
Pharmacokinetics: 
 Clonidine is well absorbed after oral administration. Since it is subjected to 
little or no presystemic elimination, its bioavailability is nearly 100%. Peak plasma 
concentrations are achieved 90 minutes after an oral dose. Clonidine is widely 
distributed throughout most tissues. Clonidine is 20 to 40% bound to plasma 
proteins. Good correlation exists between plasma concentration and its 
pharmacological effects. Although clonidine may cross the placenta it does not 
reach concentrations sufficient to affect the fetus. A transdermal delivery patch 
releases the drug at a constant rate for a week.    
 Clonidine is approximately forty percent cleared by metabolism, 
predominantly in the liver to inactive metabolites and approximately sixty percent 
is excreted unchanged in urine.35 
Mechanism of action: 
 Clonidine is the best characterized α2 adrenoceptor agonist.  2 receptors are 
located centrally and peripherally. Clonidine produces its effects by binding to 2 
receptors of which there are three types (A, B, C), each with its own area of 
anatomical predominance. 
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 2A Receptors 
 Most predominant and broadly distributed subtype 
 Concentrated in the locus ceruleus, cortex, amygdala, septum, hippocampus 
and hypothalamus. 
 Mediate sedation, analgesia, and sympatholysis. 
2B Receptors 
 Mainly restricted to thalamus. 
 Mediate sedation, vasoconstriction and possibly antishivering mechanism.  
2C Receptors 
 High densities in the hippocampus, the olfactory system, the striatum and the 
cerebral cortex 
Less is known about the effects of Clonidine on 2B and 2C adrenoceptors. 
Each of these subtype is a Gi/Go protein coupled receptor, when activated by 
agonists leads to suppression of voltage gated calcium channels and activation of 
potassium channels. This interaction suppresses adenyl cyclase activity and 
phospholipase C activity. 
Clonidine, an imidazoline derivative also binds to imidazoline binding site 
(IBS) located throughout the body and in the CNS. There are 3 subtypes of IBS: I1, 
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I2 and I3. Clonidine has greater affinity for I1 IBS which is involved in the control 
of blood pressure.32  
 The central hypotensive action of Clonidine needs both I1 IBS and 2 
adrenoceptors to produce their central sympatholytic response. Clonidine appears 
to be more selective for 2 adrenoceptors than for I1 IBS.36  
Pharmacological effects: 
 The major pharmacological effects of Clonidine involve changes in blood 
pressure and heart rate. 
 Stimulation of these 2 receptors brings about a decrease in sympathetic 
outflow from the CNS, which in turn leads to decreases in peripheral vascular 
resistance and blood pressure. Clonidine also produces bradycardia as a result of a 
centrally induced facilitation of the vagus nerve and stimulation of cardiac 
prejunctional α2-adrenergic receptors. The ability of Clonidine to produce an 
antihypertensive effect depends not only to interact with 2-receptor, but also to 
gain entry into the CNS.37 
 Characteristic central effects of Clonidine are sedation, anxiolysis and 
hypnosis. Stimulation of 2 adrenoceptors in locus ceruleus inhibits 
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neurotransmitter release which causes sedation.32  The central action also reduces 
salivary flow, intestinal motor activity and gastric acid secretion. When 
administered by mouth preoperatively, it reduces the Minimum Alveolar 
Concentration (MAC) of inhalational anaesthetic agents.38 
 Clonidine mediates its analgesic effects primarily through the spinal dorsal 
horn 2 adrenoceptors on primary afferents and interneurons, as well as the 
descending noradrenergic pathway.39 It produces analgesia without respiratory 
depression and it is associated with dose dependant sedation, hypotension and 
bradycardia. These factors prolong local anaesthetic neuraxial blockade and 
provide immediate postoperative analgesia. Currently, clonidine is approved for 
epidural use for treatment of chronic pain.40 
Administered as preoperative medication clonidine produces sedation and 
attenuation of the autonomic nervous system reflex responses [hypertension, 
tachycardia, catecholamine release] associated with preoperative anxiety and 
surgical stimulation. It also reduces the incidence of suspected or documented 
myocardial ischemia in patients with coronary artery disease.41 
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Adverse Effects:      
 Initially, sedation and dry mouth are encountered and usually subside in two 
to three weeks. It may aggravate depressive illness. In the early stage of treatment 
there may be a little fluid retention and weight gain which are usually transient. It 
commonly causes skin rashes and constipation. Other occasional side effects 
include dizziness, headache, nausea, euphoria and rarely, impotence.42 
Therapeutic Indications: 
 Hypertension 
Major therapeutic use of clonidine is in the treatment of hypertension. 
Clonidine is especially useful in patients with renal failure since its duration of 
action is not appreciably altered by renal disease and it does not compromise renal 
blood flow.43 
 Prophylaxis of migraine or recurrent vascular headache 
 Treatment of  menopausal hot flushes 
 In management of severe cancer pain 
 Anxiety disorders. Useful as a last line anxiolytic in patients 
unresponsive to standard treatment 
 Atrial fibrillation 
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 Diarrhoea, especially in diabetic neuropathy 
 Antipsychotic induced akathisia, tardive dyskinesia 
 Growth retardation as it stimulates growth hormone secretion 
 Attention deficit hyperactivity disorder as an adjunct to stimulant 
therapy 
 Tourette’s syndrome 
 Symptomatic treatment of opioid and alcohol withdrawal 
 Diagnosis of pheochromocytoma  
 Clonidine is useful in selected patients receiving anaesthesia because 
it may decrease the requirement for anaesthetic and increase 
hemodynamic stability   
 
Precautions:  
 Clonidine should be used with caution in patients with cerebrovascular 
disease, ischemic heart disease, peripheral vascular disorders, renal impairment, 
occlusive peripheral vascular disorders such as Raynaud’s disease or those with a 
history of depression.  Intravenous injections of clonidine should be given 
slowly to avoid a possible transient pressor effect. 
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Interactions: 
 Hypotensive effect of Clonidine may be enhanced by diuretics, other 
antihypertensives, and drugs that cause hypotension. Tricyclic antidepressants may 
antagonize the hypotensive effect. The sedative effect of Clonidine may be 
enhanced by CNS depressants.35 
Animal models for evaluation of sedative activity 44 
1. Open field test 
2. Hole-board test 
3. Combined open field test 
4. EEG analysis from rat brain by telemetry 
5. Method of intermittent observations 
6. Spontaneous locomotor activity testing with Actophotometer  
Animal models for evaluation of hypnotic activity 44 
1. Potentiation of hexobarbital sleeping time 
2. Experimental insomnia in rats 
3. EEG registration in conscious cats 
4. Prolongation of Ketamine induced sleeping time 
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Animal models for evaluation of antianxiety activity 44 
1. Foot shock induced aggression 
2. Isolation – induced aggression 
3. Antianxiety test in mice 
4. Anticipatory     anxiety in mice 
5. Social interaction in rats 
6. Elevated plus maze test 
7. Water maze test 
8. Staircase test 
9. Cork gnawing test 
10. Distress vocalization in rat pups 
11. Light Dark – model 
12. Schedule induced polydipsia in rats 
13. Four plate test in mice 
14. Foot shock induced freezing behaviour in rats  
15. Acoustic startle response in rats 
16. Unconditioned conflict procedure 
17. Plasma catecholamine level measurement during and after stress  
18. Electrical stimulation of the brain 
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19. Pharmacologic manipulations (drug discrimination tests)6 
- FG- 7142 induced anxiety 
- Caffeine induced anxiety 
- Yohimbine induced anxiety 
- Flumazenil induced anxiety 
- Pentylenetetrazole induced anxiety 
- Piperoxane induced anxiety 
- Cocaine induced anxiety   
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
Study centre: 
 This study was carried out in the Institute of Pharmacology and Central 
animal house, Madurai Medical College, Madurai. 
Period of study: 
 The study was conducted for a period of eight months from 15-09-2009 to 
11-05-2010, after obtaining ethical clearance from the Institutional Animal Ethical 
committee, Madurai Medical College, Madurai. 
Materials required for the study 
1. Animals  : Sixty inbred male albino mice 
2. Drugs  : Injection Diazepam 
     Injection Ketamine 
     Tablet Clonidine 
                        Pentylenetetrazole dry powder 
     Water for injection 
54 
 
              Normal saline 
3. Instruments : Actophotometer  
1. Animals: 
Inbred male albino mice from Central animal house, Madurai Medical 
College were utilized in this study. Sixty male albino mice each weighing 18 to 25 
grams were included in the study. Animals were allowed standard diet and tap 
water ad libitum. 
2. Standard drug: 
 Injection Diazepam is mixed with normal saline to obtain a solution of 
concentration 0.01 mg/ml and is administered intraperitoneally at the dose of 1.5 
mg/kg.45 
3. Ketamine: 
 Injection Ketamine is mixed with water for injection to obtain a solution of 
concentration 10 mg/ml and is administered intraperitoneally at the dose of 100 
mg/kg. 45 
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4. Test drug: 
 Tablet Clonidine was dissolved in water for injection and administered 
intraperitoneally at graded doses of 0.05 mg/kg and 0.1 mg/kg. 6 
5. Pentylenetetrazole 
 Pentylenetetrazole was dissolved in cold saline and administered 
intraperitoneally at the dose of 5 mg/kg to induce anxiety.46 
6. Water for injection: 
 Water for injection was administered intraperitoneally to control group of 
animals. 
7. Normal saline: 
 Normal saline was used as a vehicle for diazepam and pentylenetetrazole.  
8. Actophotometer: 
 The Digital Actophotometer is designed to study the spontaneous or induced 
locomotor activity in small animals like mice or rats. This apparatus uses optical 
sensors and emitters to record the horizontal movement of the animals on a four 
digit electronic counter display. 
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Methodology: 
 (I) Testing of Spontaneous Locomotor Activity (SMA) using 
Actophotometer: 
 24 male mice each weighing 18-25 grams were grouped into four with six 
animals in each group. The total number of counts made by each animal in the 
actophotometer for a period of 10 minutes was observed. The control group of 
mice received water for injection intraperitoneally, standard group of mice 
received injection Diazepam 1.5 mg/kg intraperitoneally and the test groups of 
mice received Clonidine aqueous preparation 0.05 mg/kg and 0.1 mg/kg 
intraperitoneally. 
Control group 
 
Water for injection i.p. 
 
Standard group 
 
Inj. Diazepam 1.5 mg/kg i.p. 
 
Test group I 
 
Aqueous preparation of Clonidine 0.05 mg/kg 
i.p. 
Test group II 
 
Aqueous preparation of Clonidine 0.1 mg/kg 
i.p. 
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After 30 minutes of drug administration Spontaneous Motor Activity (SMA) 
for each animal for a period of 10 minutes was observed and the observations were 
tabulated and analyzed statistically using unpaired Student’s t-test. 
 (II) Testing of Hypnotic activity by Prolongation of Ketamine 
induced sleeping time: 
 18 male albino mice were divided into 3 groups with 6 animals in each 
group. Prior to 30 minutes of administration of Ketamine 100 mg/kg 
intraperitoneally, the control group of animals received water for injection 
intraperitoneally, standard group of animals received injection Diazepam 1.5 
mg/kg intraperitoneally and test group of animals received 0.1 mg/kg of aqueous 
preparation of Clonidine intraperitoneally which was the optimum dose that 
produced sedative effect. 
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Control group 
 
Water for injection i.p. + Inj. Ketamine 100 
mg/kg i.p. 
Standard group 
 
Inj. Diazepam 1.5 mg/kg i.p. + Inj. Ketamine 
100 mg/kg i.p. 
Test group 
 
Aqueous preparation of Clonidine  0.1 mg/kg 
i.p.+ Inj. Ketamine 100 mg/kg i.p. 
  
The time at which the righting reflex is lost was taken as onset of sleep and 
the duration between the time at which the righting reflex is lost and is regained 
was taken as duration of sleep.45  The onset and duration of sleep were compared 
between test, control and standard groups. The results were tabulated and analyzed 
statistically using unpaired Student’s t-test. 
 (III) Pentylenetetrazole induced Anxiety: 
 18 adult male naive mice weighing 18-25 grams were divided into three 
groups of 6 animals in each group namely control, standard, and test groups. 30 
minutes prior to administration of pentylenetetrazole 5 mg/kg intraperitoneally, 
Control group of animals received water for injection intraperitoneally, Standard 
group of animals received injection Diazepam 1.5 mg/kg intraperitoneally and Test 
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group of animals received 0.1 mg/kg of aqueous preparation of Clonidine 
intraperitoneally which was the optimum dose that produced sedative effect. 
 Control group 
 
Water for injection i.p. + Inj. 
Pentylenetetrazole 5 mg/kg i.p.    
Standard group 
 
Inj. Diazepam 1.5 mg/kg i.p. + Inj. 
Pentylenetetrazole 5 mg/kg i.p.  
Test group 
 
Aqueous preparation of Clonidine  0.1 mg/kg 
i.p. +  Inj. Pentylenetetrazole 5 mg/kg i.p.  
 
After pentylenetetrazole administration the animals were placed in isolation 
and observed individually for grooming activity. The number of bouts of grooming 
and the duration of grooming activity were observed for 10 minutes for each 
animal. The results were tabulated and analyzed statistically using Student’s t-test. 
 
 
 
  
 
 
 
 
RESULTS 
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RESULTS 
In the present study, 60 naive male adult albino mice were selected and 
evaluated for sedative, hypnotic and anxiolytic effects. Sedative effect was 
evaluated by spontaneous locomotor activity in Actophotometer, Hypnotic effect 
by prolongation of Ketamine induced sleeping time and Anxiolytic effect was 
evaluated by pentylenetetrazole induced grooming. 
Sedative effect: 
Sedative effect was evaluated by using actophotometer. The spontaneous 
locomotor activity made by each mouse was noted in control, standard and test 
groups, 30 minutes after the administration of water for injection, diazepam and 
clonidine respectively. The average number of counts for control group of mice 
was 615.83  10.25. The average number of counts for standard group of mice was 
258.83  94.36. The average number of counts for test group I was 564.67  
70.73.The average number of counts for test group II was 240  57.23. The results 
were tabulated in Table I and analyzed using unpaired student’s “t” test. The 
sedative effect was not statistically significant (P > 0.05) for the test group I in 
comparison with control group. The sedative effect was highly significant (P < 
0.001) for both the standard and test group II in comparison with control group  
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TABLE I 
SEDATIVE EFFECT 
 
 
GROUP TREATMENT 
COUNTS AFTER 30 MIN 
( MEAN  SD) 
CONTROL Water for Injection 615.83  10.25 
STANDARD Diazepam 258.83  94.36 *** 
TEST I Clonidine 564.67  70.73 * 
TEST II Clonidine 240  57.23 *** 
 
 
 
Control Vs Test I            - * P>0.05  
 
Control Vs Standard & Test II    - *** P<0.001 
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statistically. Hence the dose of aqueous preparation of clonidine 0.1 mg/kg was 
used in the test group for hypnotic effect and anxiolytic effect. 
Hypnotic effect: 
 Hypnotic effect is measured by prolongation of Ketamine induced sleeping 
time. The onset and duration of sleep is compared between each group of animals. 
The average onset and duration in control group of mice is 115  33.96 and 588.33 
 103.28 seconds respectively. The average onset and duration in standard group of 
mice is 57.16  9.54 and 1925.83  286.3 seconds respectively. The average onset 
and duration in test group of mice is 61.5  6.02 and 1103  99.56 seconds 
respectively. The results were tabulated in Table II and analyzed using unpaired 
student’s t-test. In comparison with control group of mice, the hypnotic effect is 
highly significant (P<0.001) for standard and test group of mice statistically.     
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TABLE II 
HYPNOTIC EFFECT 
 
GROUP TREATMENT 
ONSET 
( MEAN  SD) 
DURATION 
( MEAN  SD) 
CONTROL Water for Injection + Ketamine 115  33.96 588.33  103.28 
STANDARD Diazepam + Ketamine 57.17  9.54 *** 1925.83  286.3 *** 
TEST Clonidine + Ketamine 61.5  6.02 *** 1103  99.56 *** 
 
 
Onset      :  Control Vs Standard & Test  - *** P<0.001  
 
Duration:  Control Vs Standard & Test  - *** P<0.001 
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Anxiolytic effect: 
 The animals were observed individually for grooming activity after 
pentylenetetrazole administration. Anxiolytic effect was measured by reduction in 
the number of bouts and duration of grooming induced by pentylenetetrazole.  
Both the standard and the test group of animals showed reduction in the number of 
grooming bouts as well as duration of grooming. The average number and duration 
of bouts in control group of mice is 28.83  9.13 and 51.33  7.39 seconds 
respectively. The average number and duration of bouts in standard group of mice 
is 9.67  4.03 and 24.67  6.5 seconds respectively. The average number and 
duration of bouts in test group of mice is 11.83  3.87 and 21  2.83 seconds 
respectively. The results were tabulated in Table III and analyzed statistically using 
unpaired student’s t-test. The results were highly significant (P < 0.001) for both 
test and standard groups in comparison with control group statistically. 
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TABLE III 
ANXIOLYTIC EFFECT 
 
GROUP TREATMENT 
NUMBER OF 
BOUTS 
( MEAN  SD) 
 
DURATION OF 
BOUTS 
( MEAN  SD) 
 
CONTROL Water for Injection + 
Pentylenetetrazole 28.83  9.13 51.33  7.39 
STANDARD Diazepam + 
Pentylenetetrazole 9.67  4.03 *** 24.67  6.5 *** 
TEST 
Clonidine + 
Pentylenetetrazole 11.83  3.87 *** 21  2.83 *** 
 
 
Bouts      :  Control Vs Standard & Test  - *** P<0.001 
 
Duration: Control Vs Standard & Test  - *** P<0.001 
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DISCUSSION 
Sedative, hypnotic, and anxiolytic drugs are commonly prescribed for the 
treatment of sleep and anxiety disorders. Their sedative, hypnotic and anxiolytic 
effects are also useful in anaesthetic practice as preanaesthetic medication. 
Benzodiazepines are commonly used drugs in preanaesthetic medication. 
 In the present study sedative, hypnotic and anxiolytic effects of clonidine is 
evaluated in comparison with diazepam in mice. From the results, it was observed 
that clonidine in the dose of 0.05 mg/kg had no significant sedative effect but 
showed significant sedative effect at the dose of 0.1 mg/kg in comparison with the 
control. Hence the same sedative dose of clonidine (0.1 mg/kg) was used in the test 
group for the evaluation of hypnotic and anxiolytic effects.  
Hypnotic activity was evaluated by prolongation of ketamine induced 
sleeping time.  
 Clonidine exerts its sedative, hypnotic and anxiolytic effects by acting on the 
2A receptor subtype of adrenergic receptors which are present abundantly in the 
locus ceruleus nucleus. 
 2A receptor subtype is pivotal for both sedative and analgesic effects. 
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The quality of sedation produced by 2 agonists differs from sedation 
produced by drugs that act on GABA receptors such as midazolam. Clonidine 
produces sedation by decreasing the sympathetic nervous system activity and the 
level of arousal. Clonidine lacks the psychotropic quality of benzodiazepines and 
causes a state of sedation more similar to normal sleepiness, where a patient can be 
easily aroused. Drugs that activate GABA receptors produce a clouding of 
consciousness and can cause paradoxical agitation as well as tolerance or 
dependence. Clonidine is devoid of respiratory depressant action and lacks the 
negative effects on cognition, memory and behaviour as seen with midazolam.47 
 In our study clonidine showed a significant prolongation of ketamine 
induced sleeping time. Several lines of evidence suggest that 2 adrenergic activity 
is involved in the mechanism of anaesthesia induced sleeping time. So 2A receptor 
is a possible anaesthetic target.  
Clonidine also exerts additional beneficial effects during general 
anaesthesia. Norepinephrine release is increased in the posterior hypothalamus 
during emergence from sevofluorane or halothane anaesthesia. Norepinephrine 
release is modulated via presynaptic auto receptors. Activation of these receptors 
by norepinephrine or exogenously administered drugs like clonidine, inhibit the 
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release of norepinephrine and reduce the adverse effects due to sympathetic 
stimulation. 
 The results of the present study were in agreement with the study by Bernard 
Delbarre and Henri Shmitt, where clonidine induced a loss of righting reflex in 
chickens and prolonged the sleeping time induced by chloral hydrate in mice.48 
 Anxiolytic effect was evaluated by observing the grooming effect induced 
by pentylenetetrazole in the dose of 5 mg/kg intraperitoneally. Self grooming is an 
important part of animal behavioural repertoire, which in rodents has long been 
considered as a complex ethologically “rich” response, particularly sensitive to 
various endogenous or exogenous factors. 
 Grooming normally proceeds in a cephalocaudal direction and consists of 
licking the paws, washing movements over head, fur licking and tail/genitals 
cleaning. Pentylenetetrazole is a powerful CNS stimulant which causes 
convulsions in high doses and produces anxiety in low doses. Anxiety induces 
increased grooming activity in rodents.49 
 In this study there was a highly significant reduction in number and duration 
of grooming bouts with clonidine in comparison with the control statistically. 
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 The results of this study were in agreement with the study by Tornatzky W, 
Miczek KA, where clonidine showed significant anxiolytic effect in rodents during 
acute social stress situation.50  
 In the present study clonidine showed significant sedative, hypnotic and 
anxiolytic effects. Several other studies have demonstrated the analgesic effect of 
clonidine which is due to its actions on 2 adrenoceptors of dorsal horn. Hence 
combining clonidine with opioids will enable lower doses to be used while 
enhancing sedation and analgesia.39  
 All these properties make clonidine a very useful drug in premedication.  
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CONCLUSION 
 Sleep & anxiety disorders are common nowadays and hence several classes 
of sedative, hypnotic and anxiolytics are widely prescribed. Sedative, hypnotic and 
anxiolytic effects of these drugs are used in anaesthetic practice, mainly as 
preanaesthetic medication. 
 Benzodiazepines are the most commonly used sedative, hypnotic, and 
anxiolytic drugs. They are used as a slow inducing agent in general anaesthesia and 
also as a preanaesthetic agent. Benzodiazepines can cause several unwanted side-
effects like tolerance, dependence and withdrawal symptoms. Acute overdose may 
result in respiratory depression.  
 α2-adrenoceptor agonists in anaesthetic practice is limited despite an 
increasing evidence promoting their usefulness. The α2-adrenoceptor agonist 
clonidine has been used for 30 years as a centrally acting antihypertensive agent, 
and also found to be useful in psychiatric disorders. It is gaining popularity in 
anaesthetic practice for the beneficial effects it exerts over a number of organ 
systems. 
 From the present study a significant sedative, hypnotic and anxiolytic effects 
of clonidine were proved to be present. Clonidine was found to have beneficial 
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effects like reduced bronchospasm in asthmatics, analgesia and a greater degree of 
cardiovascular stability by reducing the catecholamine levels and these properties 
are useful in anaesthesia. It also reduces the anaesthetic requirement by reducing 
Minimum Alveolar Concentration (MAC). Other possible benefits include 
decreased post operative shivering, inhibition of opioid induced muscle rigidity, 
and attenuation of opioid withdrawal symptoms.   
 Further clinical studies to evaluate the safety, will render clonidine a popular 
preanaesthetic agent, especially in situations causing adverse effects due to 
sympathetic release. 
 
 
 
  
 
 
 
 
 
BIBLIOGRAPHY 
 
 
BIBLIOGRAPHY 
1)   Eric A.Nofzinger et al. The neurobiology of sleep in relation to mental 
illness. In: Dennis S.Charney, Eric J.Nestler, Benjamin S.Bunney. 
Neurobiology of Mental Illness, Oxford University Press; 1999; 915. 
2) Constance A.Moore, Robert L.Williams and Max Hirshkowitz. Sleep 
Disorders. In: Benjamin J.Sadock, Virginia A.Sadock. Kaplan and Sadock’s 
Comprehensive Textbook of Psychiatry, Volume II, Seventh edition, Lippincott 
Williams and Wilkins; 2000; 1677-1687. 
3) Psychotropic drugs. In: Peter N. Bennet, Morris J. Brown. Clinical 
pharmacology, 10th edition, Churchill Livingstone Elsevier; 2008; 351-357. 
4) Psychiatry and medicine. In: Michael Gelder, Dennis Gath, Richard Mayou, 
Philip Cowen. Oxford Textbook of Psychiatry, Third edition, Oxford University 
Press; 1996; 409-413. 
5) Allan H. Ropper, Martin A. Samuels. Adams & Victor’s Principles of 
Neurobiology, Ninth edition, Mcgraw Hill; 2009; 374-487. 
6) S. K. Kulkarni. Practical Pharmacology and Clinical Pharmacoloy, First 
Edition, Vallabh Publications; 2008; 43, 151, 263. 
7) Dennis S.Charney, S.John Mihic, and R.Adron Harris. Hypnotics and 
Sedatives. In: Laurence L.Brunton, Joh S.Lazo, Keith L.Parker. Goodman & 
Gilman’s The Pharmacological Basis of Therapeutics, Eleventh edition, 
McGraw-Hill; 2006; 256, 401-452. 
8) General Anaesthetics. In: R. S. Satoskar, S. D. Bhandarkar, Nirmala N. Rege, 
R. R. Satoskar. Pharmacology and Pharmacotherapeutics, Twenty first edition, 
Popular Prakashan; 2009; 103. 
9) JN. Vyas, Dinesh Tyagi. Anxiety Disorders. In: JN. Vyas, Niraj Ahuja. 
Textbook of Postgraduate Psychiatry, Second edition, Jaypee; 1999; 167-252. 
10) C.M.C.Allen, C.J.Lueck, M.Dennis. Neurological disease. In: Nicholas A. 
Boon, Nicki R. Colledge, Brian R. Walker, John A.A. Hunter. Davidson’s 
Principles & Practice of Medicine, 20th Edition, Churchill Livingstone Elsevier; 
2006; 1177. 
11) Paul Reading. Sleep disorders. In: Michael Donaghy. Brain’s Diseases of 
the Nervous System, Twelfth Edition, Oxford University Press; 2009; 943. 
12) Charles A.Czeisler, John W.Winkelman, Gary S.Richardson. Sleep 
Disorders. In: Anthony S.Fauci, Eugene Braunwald, Dennis L.Kasper, Stephen 
L.Hauser, Dan L.Longo, J.Larry Jameson, Joseph Loscalzo. Harrison’s 
Principles of Internal Medicine, Volume I, 17th Edition, McGraw Hill; 2008; 
175-176. 
13) Hypnotics. In: Heinz Lullmann, Albert Ziegler, Klaus Mohr, Detlef 
Bieger. Colour atlas of Pharmacology, 2nd Edition, Thieme Stuttgart – 
Newyork; 2000; 224. 
14) Jacqueline Carinhas McGregor. Anxiety Disorders. In: Robert E. Rakel, 
Edward T. Bope. Conn’s Current therapy 2009, Saunders Elsevier; 2009; 1111-
1112. 
15) Anxiety Disorders. In: Benjamin James Sadock, Virginia Alcott Sadock. 
Kaplan & Sadock’s Synopsis of Psychiatry   Behavioral Sciences / Clinical 
Psychiatry, Tenth Edition, Wolters Kluwer Health-Lippincott Williams and 
Wilkins; 2007; 579. 
16) Peter Roy Byrne, Dane Wingerson, Deborah Cowley, Stephen Dager. 
Psychopharmacologic Treatment of Panic, Generalized Anxiety Disorder, and 
Social Phobia. In: Psychiatric Clinics of North America, Volume 16, Number 4; 
December 1993; 720. 
17) John M.Dopp and Bradley G.Phillips. Sleep Disorders. In: Joseph T. Dipro, 
Robert L. Talbert, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. 
Pharmacotherapy A Pathophysiologic Approach, Seventh Edition, Mcgraw 
Hill; 2008; 1164-1195. 
18) Anxiolytics and Hypnotics. In: HL Sharma, KK Sharma. Principles of 
Pharmacology, First Edition, Paras Medical Publishers; 2008; 450-458. 
19) Manvir Bhatia. Sleep disorders. In: Siddharth N. Shah. API Textbook of 
Medicine, 8th Edition, The Association of Physicians of India; 2008; 1153. 
20) J.Lance Lichtor and Vincent J.Collins. Benzodiazepines. In: Vincent 
J.Collins. Physiologic and Pharmacologic Bases of Anesthesia, Williams & 
Wilkins; 1996; 530. 
21) Sedative-Hypnotics. In: KD Tripathi. Essentials of Medical Pharmacology, 
Sixth edition, Jaypee; 2008; 394-397. 
22) Anxiolytic and hypnotic drugs. In: H P Rang, M M Dale, J M Ritter, R J 
Flower. Rang and Dale’s Pharmacology, Sixth Edition, Churchill Livingstone 
Elsevier; 2007; 537-540. 
23) Stuart J. Eisendrath, Jonathan E. Lichtmacher. Psychiatric Disorders. In: 
Stephen J. McPhee, Maxine A. Papadakis. Lange 2009 Current Medical 
Diagnosis & Treatment, Forty eighth edition, Mcgraw Hill; 2009; 913-918. 
24) Anxiolytic and Hypnotic Drugs. In: Richard Finkel, Michelle A. Clark, 
Luigi X. Cubeddu, Richard A. Harvey, Pamela C. Champe. Lippincott’s 
Illustrated Reviews: Pharmacology, Third edition, Wolters Kluwer Health-
Lippincott Williams and Wilkins; 2009; 113. 
25) Anthony J.Trevor & Walter L.Way. Sedative-Hypnotic Drugs. In: Bertram 
G.Katzung, Susan B.Masters, Anthony J.Trevor. Basic and Clinical 
Pharmacology, 11th Edition, Tata McGraw-Hill; 2009; 374. 
26) Lakshmi N.Ravindran, Murray B.Stein. Anxiety Disorders: Somatic 
Treatment. In: Benjamin J.Sadock, Virginia A.Sadock, Pedro Ruiz. Kaplan and 
Sadock’s Comprehensive Textbook of Psychiatry, Volume I, Ninth edition, 
Lippincott Williams and Wilkins; 2009; 1907. 
27) Shyam S Sharma, Prem Chawla. Anxiolytic and Hypnotic Drugs. In: S D 
Seth, Vimlesh Seth. Textbook of Pharmacology, Third Edition,  Elsevier; 2009; 
III.96-100. 
28) Psychological medicine. In: Parveen Kumar, Michael Clark. Kumar & 
Clark’s Clinical Medicine, Seventh edition, Saunders Elsevier; 2009; 1209. 
29) Stuart A. Forman, Janet Chou, Gary R. Strichartz and Eng H. Lo. 
Pharmacology of GABAergic and Glutamatergic Neurotransmission. In: David 
E. Golan, Armen H. Tashjian, Jr, Ehrin J. Armstrong, April W. Armstrong. 
Principles of Pharmacology. The pathophysiologic Basis of Drug Therapy, 
Second Edition, Wolters Kluwer Health-Lippincott Williams and Wilkins; 
2008; 169-170. 
30) Samir Kumar Praharaj, Prathap Tharyan, Smita N. Deshpande. Treatment 
Options in Anxiety Disorders. In: Kamlesh Kohli, Madhur Gupta, Sheela 
Tejwani. Contemporary Perspectives on Clinical Pharmacotherapeutics, First 
Edition, Elsevier; 2006; 169-170. 
31) Adrenergic Agonists & Antagonists. In: G.Edward Morgan, Maged 
S.Mikhail, Michael J.Murray. Clinical Anesthesiology, Fourth edition, Lange 
Medical Books/ McGraw-Hill; 2006; 247-248. 
32) Eric Hollander, Jennifer N. Petras. 2-Adrenergic Receptor Agonists: 
Clonidine and Guanfacine. In: Benjamin J.Sadock, Virginia A.Sadock, Pedro 
Ruiz. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, Volume II, 
Ninth edition, Lippincott Williams and Wilkins; 2009; 3004-3005. 
33) Sedative and antiepileptic drugs. In: Alan R Aitkenhead, Graham Smith, 
David J Rowbotham. Textbook of Anaesthesia, Fifth Edition, Churchill 
Livingstone Elsevier; 2007; 103. 
34) Cardiovascular Drugs. In: Sean C Sweetman. Martindale The Complete 
drug reference, Thirty third edition, PhP Pharmaceutical Press; 2002; 860. 
35) Colin Dollery, Ala Boobis, Michael Rawlins Simon Thomas, Martin 
Wilkins. Therapeutic Drugs, Second edition, Churchill Livingstone; 1999; 296. 
36) David A.Williams. Central and Peripheral Sympatholytics and Vasodilators. 
In: Thomas L.Lemke, David A.Williams, Victoria F.Roche, S.William Zito. 
Foye’s Principles of Medicinal Chemistry, Sixth Edition, Wolters Kluwer 
Health-Lippincott Williams and Wilkins; 2008; 778. 
37) Rodney L.Johnson. Adrenergic Agents. In: John H. Block, John M. Beale, 
Jr . Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical 
Chemistry, Eleventh edition, Lippincott Williams and Wilkins; 2004; 533. 
38) Steven M Yentis, Nicholas P Hirsch, Gary B Smith. Anaesthesia and 
Intensive Care A - Z  An Encyclopaedia of Principles and Practice, Fourth 
Edition, Churchill Livingstone Elsevier; 2009; 127. 
39) Robert W.Hurley and Christopher L.Wu. Acute Postoperative Pain. In: 
Ronald D. Miller, Lars I. Eriksson, Lee A. Fleisher, Jeanine P. Wiener-Kronish, 
William L. Young. Miller,s Anesthesia, Volume 2, Seventh edition, Churchill 
Livingstone Elsevier; 2010; 2767. 
40) J.C.Gerancher, Spencer S.Liu. Complications of Neuraxial 
(Spinal/Epidural/Caudal) Anesthesia. In: Jonathan L. Benumof, Lawrence J. 
Saidman. Anesthesia & Perioperative Complications, Second edition, Mosby; 
1999; 60. 
41) Rachel Dotson, Jeanine P.Wiener-Kronish, and Temitayo Ajayi. 
Preoperative evaluation and medication. In: Robert K. Stoelting, Ronald D. 
Miller. Basics of Anesthesia, Fifth edition, Churchill Livingstone Elsevier; 
2007; 171. 
42) Drugs used for their effects on vascular tone and cardiac contractility. In: 
M.D. Vickers, M. Morgan, P.S.J. Spencer, M.S. Read. Drugs in Anaesthetic and 
Intensive Care Practice, Eighth Edition, Butterworth-Heinemann; 1999; 345. 
43) David P.Westfall. Antihypertensive Drugs. In: Charles R. Craig, Robert E. 
Stitzel. Modern Pharmacology with Clinical Applications, 6th Edition, 
Lippincott Williams and Wilkins; 2004; 237. 
44) H.Gerhard Vogel, Wolfgang H.Vogel. Drug Discovery and Evaluation. 
Pharmacological Assays; Springer-Verlag Berlin Heideiberg; 1997; 204-269. 
45) M.Rabbani, S.E.Sajjadi and A.Mohmmadi. Evaluation of the anxiolytic 
effect of Nepeta persica Boiss. in mice. In: http://ecam.Oxfordjournals 
.org/cgi/content/full/5/2/181 - Oxford journals 
46) Allan V.Kalueff and Pentti Tuohimaa. Mouse grooming microstructure is a 
reliable anxiety marker bidirectionally sensitive to GABAergic drugs. In: 
European Journal of Pharmacology, Volume 508, issues 1-3, 31 January 2005, 
147-153. 
47) Sujatha Basker, Georgene Singh, Rebecca Jacob. Clonidine in Paediatrics – 
A review. In: Indian Journal of Anaesthesia; 2009; 53(3); 271. 
48) Bernard Delbarre and Henri Schmitt. Sedative effects of α-ympathomimetic 
drugs and their antagonism by adrenergic and cholinergic blocking drugs. In: 
European Journal of Pharmacology, Volume 13, issues 3, February 1971; 356-
363. 
49) A.V.Kalueff, Y.R.Lou, I.Laaksi, P.Tuohimaa. Increased grooming behavior 
in mice lacking vitamin D receptors. In: Physiology & Behavior , Volume 82, 
issues 2-3; 15 September 2004; 405-409. 
50) Tornatzky W, Miczek KA. Behavioral and autonomic responses to 
intermittent social stress: differential protection by clonidine and metoprolol. 
In: Psychopharmacology (Berl). ; 1994 Nov; 116(3):346-56. 
 
 
 
 
 
 
  
 
 
 
 
 
ANNEXURES 
 
 
  
Spontaneous locomotor acivity in 
actophotometer
564.67
240258.83
615.83
70.73
57.2394.36
10.25
0
100
200
300
400
500
600
700
Control Standard Test I Test II
C
ou
nt
s
SD
Mean
P<0.001
 
 
 
 
 
  
115
33.96
57.16
9.54
61.5
6.02
0
20
40
60
80
100
120
140
160
Ti
m
e 
in
 S
ec
on
ds
Control Standard Test
HYPNOSIS ONSET
SD (±)
Mean
P<0.001
 
 
 
 
 
  
588.33
103.28
1925.83
286.3
1103
99.56
0
500
1000
1500
2000
2500
Ti
m
e 
in
 S
ec
on
ds
Control Standard Test
HYPNOSIS DURATION
SD (±)
Mean
P<0.001
 
 
 
 
 
  
28.83
9.13
9.67
4.03
11.83
3.87
0
5
10
15
20
25
30
35
40
B
O
UT
S
Control Standard Test
ANXIETY BOUTS
SD (±)
Mean
P<0.001
 
 
 
 
  
51.33
7.39
24.67
6.5
21
2.83
0
10
20
30
40
50
60
TI
M
E 
IN
 S
EC
O
N
D
S
Control Standard Test
ANXIETY DURATION
SD (±)
Mean
P<0.001  
 
ACTOPHOTOMETER 
 
MICE UNDER KETAMINE ANAESTHESIA 
 
 
